BioWorld

Feb. 23, 2010

View Archived Issues

Viamet, Novartis Fund Targeting Metalloenzymes in $200M Deal

Viamet Pharmaceuticals Inc. signed a deal worth more than $200 million with the Novartis Option Fund to discover and develop metalloenzyme inhibitors of interest to the Swiss drugmaker. (BioWorld Today) Read More

FDA Raises Endpoint Concerns in Study of Salix Liver Drug

Read More

Blocking Backup Pathway Could Prevent Glioblastoma Comeback

Read More

New Money Scarce, so ITS Founders Chip in $13.4M

Read More

Icahn Makes Move as Genzyme Looks for Good News in 2010

Read More

White House Health Bill Adopts 12 Years for FOBs

Read More

NIH Stem Cell Definition Change 'Hugely Important'

Read More

Other News To Note

Read More

Clinic Roundup

Read More